Higher levels of C-reactive protein (CRP), a nonspecific marker of inflammation, were suggestive of an association with increased breast cancer risk, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
In this study, 943 cases from the Nurses’ Health Study (NHS) and 1,919 cases from the Women’s Health Study (WHS) were evaluated.
Results showed higher CRP levels were associated with a greater risk of breast cancer for those in the NHS (quintile 5 vs. 1: RR, 1.27; 95% CI: 0.93, 1.73; P trend = 0.02). However, no correlation between CRP levels and breast cancer risk were observed in the WHS (quintile 5 vs. 1: RR, 0.89; 95% CI: 0.76, 1.06; P trend = 0.38).
The random effect meta-analysis conducted on the data showed a slightly increased risk in women with the highest versus lowest levels of CRP (RR, 1.26; 95% CI: 1.07, 1.49).
Corresponding Author: Jun Wang, Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, 715 North Pleasant Street, Amherst, MA 01003. Phone: 413-545-0845; Fax: 413-545-1645; E-mail: junw{at}schoolph.umass.edu Background: C-reactive protein (CRP) has been evaluated as a risk factor for breast cancer in epidemiologic studies.
READ FULL ARTICLE
From cebp.aacrjournals.org
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.